Table 1.

Patient baseline and demographic data

Part	A Healthy volunteers Single ascending dose						A Sickle cell disease Single dose		B Healthy volunteers Multiple ascending dose
Voxelotor (mg) or matched placebo	Placebo	100	400	1000	2000	2800	Placebo	1000	Placebo	300	600	900
n	10	6	6	6	6	6	2	6	6	6	6	6
Age, median (range), y	34 (22–44)	33 (19–50)	33 (24–40)	33 (27–43)	36 (27–48)	35 (28–51)	27 (20–34)	31 (25–47)	34 (22–48)	30 (23–54)	38 (23–49)	40 (27–54)
Male sex, n (%)	10 (100)	6 (100)	6 (100)	6 (100)	5 (83.3)	6 (100)	1 (50)	3 (50)	6 (100)	6 (100)	6 (100)	6 (100)
Race, n (%)
Asian	0	1 (16.7)	0	2 (33.3)	0	1 (16.7)	0	0	1 (16.7)	0	0	2 (33.3)
Black	1 (10%)	0	1 (16.7)	1 (16.7)	0	2 (33.3)	2	6	0	1 (16.7)	0	0
White	9 (90%)	3 (50)	4 (66.7)	3 (50)	6	2 (33.3)	0	0	5 (83.3)	5 (83.3)	6 (100)	4 (66.7)
Other	0	2 (33.3)	1 (16.7)	0	0	1 (16.7)	0	0	0	0	0	0
BMI median (range)	24.7 (22.4–28.1)	25.7 (24.4–28.5)	25.3 (21.7–26.8)	24.7 (22.4–28.3)	25.1 (22.1–28.2)	28.5 (19.7–35.3)	25.8 (25.3–26.2)	21.9 (20.2–23.9)	26.5 (22.4–27.5)	26.5 (22.6–29.5)	24.9 (20.4–30)	26.1 (23.2–30.7)

BMI, body mass index.